Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Drug Farm Raises $27 Million for AI-based Immune-modulating Therapies

publication date: May 16, 2023

Drug Farm, a Shanghai-Connecticut biopharma, raised $27 million from China investors, the first tranche of a C round to support trials of its two lead projects, a hepatitis B candidate and a cardio-renal therapy. The company uses genetics and AI technologies to discover innovative immune-modulating therapies for hepatitis B, cancer and autoimmune diseases. Two years ago, the company closed a $56 million funding. The latest funding was led by YD Capital with participation from Jiashan County State-owned Assets Investment and Betta Capital. More details....

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital